Key result
Disease-associated mutations in the ATP and calcium binding sites of the RyR1 channel impaired its activation and regulation, which may contribute to muscle weakness in RYR1-related myopathies.
Why the study?
Patients with inherited mutations in RyR1 exhibit muscle weakness, but the functional significance of putative Ca2+ and ATP binding sites identified by structural studies required functional evaluation.
Mutations in the Ca2+ and ATP binding sites of RyR1 impair channel regulation, which may contribute to the pathophysiology of RYR1-related myopathy.
RyR1 Ca2+/ATP site mutations impair channel regulation in models; leaves open mechanistic role in human RYR1-myopathy and requires clinical validation.
The type 1 ryanodine receptor (RyR1) is an intracellular calcium (Ca 2+ ) release channel on the sarcoplasmic/endoplasmic reticulum that is required for skeletal muscle contraction. RyR1 channel activity is modulated by ligands, including the activators Ca 2+ and ATP. Patients with inherited mutations in RyR1 may exhibit muscle weakness as part of a heterogeneous, complex disorder known as RYR1 -related myopathy ( RYR1 -RM) or more recently termed RYR1-related disorders (RYR1-RD). Guided by high-resolution structures of skeletal muscle RyR1, obtained using cryogenic electron microscopy, we introduced mutations into putative Ca 2+ and ATP binding sites and studied the function of the resulting mutant channels. These mutations confirmed the functional significance of the Ca 2+ and ATP binding sites identified by structural studies based on the effects on channel regulation. Under normal conditions, Ca 2+ activates RyR1 at low concentrations (µM) and inhibits it at high concentrations (mM). Mutations in the Ca 2+ -binding site impaired both activating and inhibitory regulation of the channel, suggesting a single site for both high and low affinity Ca 2+ -dependent regulation of RyR1 function. Mutation of residues that interact with the adenine ring of ATP abrogated ATP binding to the channel, whereas mutating residues that interact with the triphosphate tail only affected the degree of activation. In addition, patients with mutations at the Ca 2+ or ATP binding sites suffer from muscle weakness, therefore impaired RyR1 channel regulation by either Ca 2+ or ATP may contribute to the pathophysiology of RYR1 -RM in some patients.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2021) studied RYR1-related myopathy. Site-directed mutagenesis of RyR1 ATP and calcium binding sites vs. Wild-type RyR1 was evaluated on RyR1 channel activation and ligand binding. Disease-associated mutations in the ATP and calcium binding sites of the RyR1 channel impaired its activation and regulation, which may contribute to muscle weakness in RYR1-related myopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: